Drug Report History #873
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v43-FR | Version v13-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2022-06-23 | Was: 2017-05-11 |
| Drug Identification Number | 02243676 | 02243676 |
| Brand name | RECOMBIVAX HB -(PRESERVATIVE FREE) | RECOMBIVAX HB -(PRESERVATIVE FREE) |
| Common or Proper name | (hepatitis B vaccine [recombinant]) | (hepatitis B vaccine [recombinant]) |
| Company Name | MERCK CANADA INC | MERCK CANADA INC |
| Ingredients | HEPATITIS B SURFACE ANTIGEN | HEPATITIS B SURFACE ANTIGEN |
| Strength(s) | 10MCG | 10MCG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR | INTRAMUSCULAR |
| Packaging size (Changed) | Updated to: 10MCG/1ML 10X1DOSE VIAL | Was: 10X1DOSEVIAL |
| Additional packaging sizes | ||
| ATC code | J07BC | J07BC |
| ATC description | VIRAL VACCINES | VIRAL VACCINES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2017-08-01 | 2017-08-01 |
| Actual start date (Changed) | Updated to: 2017-08-04 | Was: 2017-05-10 |
| Estimated end date (Changed) | Updated to: 2022-06-30 | Was: 2018-07-02 |
| Actual end date (Changed) | Updated to: 2022-06-22 | Was: |
| Shortage status (Changed) | Updated to: Resolved | Was: Actual shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: Format 1DOSE VIAL remains available. / Le format 1DOSE VIAL est encore disponible. | Was: |
| Health Canada comments |